TFFP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	22 175.00
Średni wolumen	37 137.00
Kapitalizacja rynkowa	6.75M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $-2.26 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0.0290 (1.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	King Thomas Braxton	Buy	3 110	Restricted stock units
2024-04-18	Patane Michael A	Buy	3 556	Restricted stock units
2024-04-18	Lee Catherine Chai-zon	Buy	3 556	Restricted stock units
2024-04-18	Mills Robert S	Buy	4 667	Restricted stock units
2024-04-18	Roberts Brandi	Buy	5 333	Restricted stock units

INSIDER POWER
71.21
Last 95 transactions
Buy: 4 806 950 \| Sell: 2 066 322

Wolumen Korelacja

Długi: 0.07 (neutral)

Krótki: 1.00 (very strong)

Signal:(55.953) Expect same movement, but be aware

TFF Pharmaceuticals Inc Korelacja

10 Najbardziej pozytywne korelacje
MRACW	0.954
BIOL	0.949
NRBO	0.946
KBSF	0.94
SLNH	0.939
GRNV	0.935
AVCT	0.934
AYLA	0.929
TDAC	0.927
UK	0.926

10 Najbardziej negatywne korelacje
VLYPO	-0.938
BOCH	-0.931
IART	-0.923
SLGN	-0.92
MMAC	-0.919
RFEU	-0.919
LMRK	-0.918
INNV	-0.917
LOPE	-0.914
AGFS	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TFF Pharmaceuticals Inc Korelacja - Waluta/Towar

-0.24
( neutral )

-0.64
( weak negative )

0.00
( neutral )

-0.65
( weak negative )

0.56
( weak )

0.42
( neutral )

TFF Pharmaceuticals Inc Finanse

Annual	2023
Przychody:	$733 871
Zysk brutto:	$231 391 (31.53 %)
EPS:	$-11.85

FY	2023
Przychody:	$733 871
Zysk brutto:	$231 391 (31.53 %)
EPS:	$-11.85

FY	2022
Przychody:	$0
Zysk brutto:	$-388 221 (0.00 %)
EPS:	$-26.49

FY	2021
Przychody:	$88.00
Zysk brutto:	$88.16 (100.00 %)
EPS:	$-0.00152

Financial Reports:

No articles found.

TFF Pharmaceuticals Inc

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.